23andMe Holding Co.

Hello, and welcome to 23andMe's fiscal year 2025 first quarter financial results conference call. As a reminder, this call is being recorded. At this time, all participants are on listen-only mode. After the speaker's prepared remarks, there will be a question and answer session. I would now like to turn the call over to Ian Cooney, Senior Director of Investor Relations at 23andMe, to lead off the call. Thank you. Please go ahead.

Thank you. Before we begin, I encourage everyone to go to investors.23andme.com to find the press release we issued earlier today reporting our financial results for the first quarter of fiscal 2025. A replay of today's webcast will also be available on our website. Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions for future periods, our forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled forward-looking statements in our press release, which applies to this call. Also, please refer to our SEC filings, which can be found on our website and the SEC's website, for a discussion of numerous factors that may impact our future performance. We also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliation to U.S. GAAP may be found in our earnings release. Joining us on our call today are Anne Wojcicki, our chief executive officer and co-founder, and Joe Sellsavage, our chief financial and accounting officer. Jennifer Lowe, our head of therapeutics development, will join us for Q&A. I'd now like to turn the call over to Joe.

Thank you, Ian. Hello, everyone. Reiterating what we said on our last call, the focus of the call is on the first quarter fiscal 2025 results. We will not comment on the ongoing process of reviewing potential take private proposals or strategic alternatives. This call is focused solely on the company and its earnings release, and we will not be addressing or responding to any questions regarding the aforementioned matters on this call. I'd now like to turn the call over to Anne.